The SS1P immunotoxin, which consists of PE38 linked to an anti-mesothelin antibody, has shown effectiveness in treating mesothelioma and other tumors, which overexpress mesothelin in preclinical as well as clinical trials [121]. This evidence concerns the gene MSLN and mesothelioma.